Business Context and Reporting Period
Company: Oaktree Acquisition Corp. III Life Sciences (OACC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024 (Inception: June 28, 2024)
Business Overview: The Company is a Cayman Islands exempted company and a Special Purpose Acquisition Company (SPAC) formed to effect a business combination with one or more businesses in the healthcare or healthcare-related industries (biopharmaceutical, medical devices, diagnostics, specialized healthcare services). The Company has no operating history and has not selected a specific target business as of the filing date. It is sponsored by Oaktree Acquisition Holdings III LS, LLC, an affiliate of Oaktree Capital Management, L.P.
Key Financial Metrics
| Metric | Value (as of Dec 31, 2024) |
|---|---|
| Net Income | $1,331,707 |
| Operating Expenses | $351,806 |
| Interest Income (Trust Account) | $1,588,732 |
| Cash in Trust Account | $193,579,022 |
| Cash Outside Trust Account | $1,357,044 |
| Total Assets | $195,250,622 |
| Total Liabilities | $7,746,071 |
| Shareholders' Deficit | $(6,074,471) |
| Deferred Underwriting Fees | $6,719,660 |
| Class A Shares (Public) | 19,199,029 (Subject to redemption) |
| Class B Shares (Founder) | 4,799,758 |
Material Changes and IPO Details
The Company completed its Initial Public Offering (IPO) on October 25, 2024, selling 17,500,000 units at $10.00 per unit. On October 30, 2024, underwriters partially exercised their over-allotment option, purchasing an additional 1,699,029 units. Simultaneously, the Sponsor purchased 583,981 private placement units.
- Trust Account Funding: $191,990,290 was deposited into the Trust Account ($10.00 per public unit).
- Transaction Costs: Total transaction costs were $11,587,475, comprising $3,839,806 in upfront underwriting fees, $6,719,660 in deferred underwriting fees, and $1,028,009 in other offering costs.
- Net Income Drivers: Net income for the period was driven primarily by interest earned on the Trust Account ($1.59M) and a change in the fair value of the over-allotment liability ($94,781), offset by general and administrative expenses.
Guidance, Outlook, and Risks
Outlook and Strategy: The Company intends to complete an initial business combination within 24 months of the IPO closing (by October 2026). It targets North American, British, or European companies in the life sciences sector with an enterprise value of approximately $500 million to $1.5 billion. The management team leverages Oaktree's global platform and life sciences lending experience.
Material Risks:
- Liquidation Risk: If a business combination is not consummated within 24 months, the Company will liquidate, redeeming public shares at a pro-rata share of the Trust Account (approx. $10.00 per share plus interest), and warrants will expire worthless.
- Trust Account Claims: Funds in the Trust Account could be subject to claims by creditors, potentially reducing the redemption amount below $10.00 per share. The Sponsor has agreed to indemnify the Trust Account against such claims, subject to limitations.
- Conflicts of Interest: Officers and directors have fiduciary duties to other entities (including Oaktree funds) and may have conflicts in allocating time or presenting business opportunities. Founder shares were purchased at a nominal price ($0.005/share), creating an incentive to complete a transaction even if it is not optimal for public shareholders.
- Regulatory Risks: Potential CFIUS review for foreign investment, changes in SPAC regulations (2024 SPAC Rules), and the potential application of the 1% Excise Tax on stock buybacks.
Investor Verification Checklist
- Trust Account Balance: Verify the current balance and interest accrual in the Trust Account to ensure the redemption value remains near or above $10.00 per share.
- Extension Provisions: Review the Company's ability to extend the 24-month deadline and the associated redemption rights for shareholders if an extension is sought.
- Sponsor Indemnity: Assess the financial capacity of the Sponsor (Oaktree Acquisition Holdings III LS, LLC) to satisfy indemnification obligations if third-party claims reduce the Trust Account balance.
- Target Criteria: Monitor the Company's progress in identifying a target that meets the stated criteria (healthcare sector, $500M-$1.5B enterprise value) and the timeline for due diligence.
- Warrant Terms: Review the warrant exercise price ($11.50) and redemption triggers ($18.00 per share) to understand the dilution potential and upside for warrant holders.